Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
3.15M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
1.25M
-
Shares change
-
+166K
-
Total reported value, excl. options
-
$35.3M
-
Value change
-
+$5.34M
-
Number of buys
-
2
-
Number of sells
-
-4
-
Price
-
$2.31
Significant Holders of GT Biopharma, Inc. - Common Stock (GTBP) as of Q3 2024
16 filings reported holding GTBP - GT Biopharma, Inc. - Common Stock as of Q3 2024.
GT Biopharma, Inc. - Common Stock (GTBP) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.25M shares
of 3.15M outstanding shares and own 39.58% of the company stock.
Largest 10 shareholders include DekaBank Deutsche Girozentrale (1.15M shares), BANK OF MONTREAL /CAN/ (29.9K shares), GEODE CAPITAL MANAGEMENT, LLC (15K shares), VANGUARD GROUP INC (10.5K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (10.1K shares), WELLS FARGO & COMPANY/MN (10K shares), BlackRock, Inc. (9.74K shares), UBS Group AG (3.9K shares), Tower Research Capital LLC (TRC) (1.64K shares), and MORGAN STANLEY (266 shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.